Brainomix to Present Five New Studies at ERS Congress Demonstrating the Potential of Quantitative CT in Interstitial Lung Disease (ILD)

Brainomix will present five ERS 2026 abstracts highlighting AI CT biomarkers from its FDA-cleared, CE-marked Brainomix 360 e-Lung tool, including a Phase 2a post-hoc analysis on taladegib showing increased lung volume and regression of ILD markers. Additional studies link quantitative CT findings to telomere shortening, mortality risk, and future FVC decline, plus biomarker assessment in IPF with/without pulmonary hypertension. The update is supportive of the company’s clinical-evidence trajectory but is unlikely to move markets materially on its own.

Analysis

This is more of a commercialization milestone than a revenue event. The incremental value is not in the conference itself; it is in whether third-party clinicians start treating quantitative CT as a surrogate endpoint that can be embedded into routine ILD workflows. If that happens, the economic rent likely accrues to workflow owners and imaging-platform vendors, not to point-solution AI brands, because distribution into hospital IT and PACS is the gating factor.

Second-order, the bigger winner could be fibrotic-lung drug developers and trial sponsors: better imaging stratification lowers endpoint noise, which can tighten readouts and reduce sample sizes over a 1-3 year horizon. The loser set is less obvious but includes legacy radiology reading services and any diagnostic vendor whose moat depends on subjective interpretation; AI-assisted quantification compresses the value of incremental human reads. That said, without prospective validation plus reimbursement, the monetization path remains long and most of the current signal is academic, not commercial.

Near term, expect little share-price persistence in public comps unless the conference data is unusually strong or gets paired with a real customer win. The contrarian read is that the market may be overestimating how quickly retrospective/post-hoc biomarker work turns into billable product; historically, the bottleneck is not model accuracy but workflow integration, liability, and payer acceptance. What would falsify the bear case is a visible deployment cadence with named health systems, Medicare/commercial coverage language, or prospective data showing the biomarker changes treatment decisions and outcomes.

Key Decisions for Investors

• No immediate trade in the private-company read-through; treat MEDD/WWRL as watch items only until ERS data are paired with prospective validation or commercial adoption metrics over the next 1-3 months.
• Bias modestly long GEHC on any post-ERS weakness as the cleanest public proxy for AI-enabled CT workflow adoption; downside is limited if adoption stays incremental, while upside is a software attach/margin mix story over 6-18 months.
• If ILD biomarker validation starts to be cited in trial design, add a small long in RHHBY or UTHR as a beneficiary of better patient stratification; stop if there is no follow-through in conference abstracts or protocol changes within one quarter.
• Fade any knee-jerk rally in generic AI-imaging baskets after the Congress; the risk/reward favors selling the news unless management teams announce reimbursed deployments or prospective outcomes data.
• Set a catalyst alert for ERS (Sept. 5-9): if Brainomix shows prospective, not post-hoc, evidence and named hospital pilots, reconsider a long GEHC / short broader healthcare ETF pair; otherwise stay flat.